WhatsApp: +237692052167 weight loss pills in California A new once-weekly weight-loss drug just hit a major milestone . https://weightlosspillshop.com/
Obesity medications
—Some obesity medications have approved Food and Drug Administration (FDA) indicated uses to treat adverse health outcomes that go beyond improvement in obesity alone.
—Optimal medical management acknowledges that the priority is not to just treat the weight of the patient, but to also improve the health outcomes of the patient.
—Not only is tirzepatide indicated to treat overweight and/or obesity, but tirzepatide also has an explicit FDA indication to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
—Similarly, in addition to an indicated use to treat overweight and/or obesity, semaglutide has FDA indicated uses to reduce the risk of major adverse cardiovascular events and as a treatment for noncirrhotic metabolic dysfunction associated steatohepatitis.
WhatsApp: +237692052167 weight loss pills in California A new once-weekly weight-loss drug just hit a major milestone — and it’s not a GLP-1. In a major Phase II study led by Eli Lilly, their experimental drug eloralintide helped adults with obesity lose around 20% of their body weight over 48 weeks. That’s in the same league as the blockbuster GLP-1 drugs that have transformed obesity care — but this one works in a completely different way. Here’s why scientists are buzzing! Eloralintide is a long-acting amylin analog, inspired by a natural hormone released with insulin that helps regulate appetite, slow digestion, and signal fullness to the brain. Researchers have known for decades that amylin could be a powerful weight-control target — but earlier drugs broke down too quickly or caused side-effects that limited their use. Lilly’s scientists appear to have solved that. By engineering a stable, once-weekly version, they’ve unlocked amylin’s potential at last — and the trial results show it.
Participants on the highest dose lost nearly 20% of body weight on average versus 0.4% with placebo — and with fewer GI side effects than GLP-1 drugs. Why it's significant:
It proves there’s life beyond GLP-1s in obesity science.
It could pave the way for next-gen combination therapies — pairing amylin with GLP-1 or GIP agonists for even greater effect.
It might offer simpler dosing and better tolerability, helping more people stay on treatment. As obesity therapeutics head toward a $100 billion market, eloralintide could signal the dawn of a “post-GLP-1 era” — one driven by multiple hormones, smarter biology, and real metabolic balance.
Would you take a once-weekly shot if it meant losing 1 in 5 of your body weight — without the nausea?
Obesity medications
—Some obesity medications have approved Food and Drug Administration (FDA) indicated uses to treat adverse health outcomes that go beyond improvement in obesity alone.
—Optimal medical management acknowledges that the priority is not to just treat the weight of the patient, but to also improve the health outcomes of the patient.
—Not only is tirzepatide indicated to treat overweight and/or obesity, but tirzepatide also has an explicit FDA indication to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
—Similarly, in addition to an indicated use to treat overweight and/or obesity, semaglutide has FDA indicated uses to reduce the risk of major adverse cardiovascular events and as a treatment for noncirrhotic metabolic dysfunction associated steatohepatitis.
WhatsApp: +237692052167 weight loss pills in California A new once-weekly weight-loss drug just hit a major milestone — and it’s not a GLP-1. In a major Phase II study led by Eli Lilly, their experimental drug eloralintide helped adults with obesity lose around 20% of their body weight over 48 weeks. That’s in the same league as the blockbuster GLP-1 drugs that have transformed obesity care — but this one works in a completely different way. Here’s why scientists are buzzing! Eloralintide is a long-acting amylin analog, inspired by a natural hormone released with insulin that helps regulate appetite, slow digestion, and signal fullness to the brain. Researchers have known for decades that amylin could be a powerful weight-control target — but earlier drugs broke down too quickly or caused side-effects that limited their use. Lilly’s scientists appear to have solved that. By engineering a stable, once-weekly version, they’ve unlocked amylin’s potential at last — and the trial results show it.